During this year´s AACR Annual Meeting, Washington DC, April 6 -10, ecancer caught up with VHIO´s Laura Soucek, PI of the Mouse Models of Cancer Therapies Group, to discuss her group´s pioneering work on Myc inihibition in pre-clinical mouse models.
Related Posts
CaixaImpulse to back VHIO´s development of companion diagnostic test to more precisely guide targeted therapy with PARPi
Announced last week, the third edition of the CaixaImpulse call – a funding program created by the Fundació Bancària la…
11 Jul 2017
Cancer Core Europe: a consortium to address the cancer research continuum challenge
Barcelona, 26 September 2014 – Officially announced today during a press conference at the 2014 Congress of the European Society…
26 Sep 2014
VHIO to lead phase II combination study to assess efficacy of novel anticancer agent against endometrial cancer
Announced today by Catalan biopharmaceutical company, Ability Pharmaceuticals SL, VHIO has been selected to lead a phase II clinical trial…
23 Nov 2016
Liquid biopsy of cerebrospinal fluid for less invasive, more effective ´policing´ of brain tumors
VHIO leads research proposing cerebrospinal fluid (CSF) as liquid biopsy for the early diagnosis, prognosis, therapeutic management and tracking of…
10 Nov 2015
Genomic alterations decoded for the first time in one of the most serious hereditary cancers
VHIO scientists discover a common factor among different tumours in a patient with Li-Fraumeni syndrome further to whole-genome sequencing This…
07 Oct 2013
VHIO spinout Mosaic Biomedicals: accelerating clinical trials of first-in-class therapeutic antibody for cancer
Mosaic Biomedicals SL today announced a merger with Northern Biologics Inc. that will enable the accelerated development of MSC-1, a…
19 Dec 2016
VHIO´s Laura Soucek receives ICREA professorship to further spur research of excellence at International level
ICREA – the Catalan Institution for Research and Advanced Studies, founded in 2001 with the support of the Catalan Government,…
19 Jan 2015
The Lancet Oncology: Javier Cortes´linked Comment on Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I—III breast cancer (HannaH study)
New Herceptin® delivery method could vastly simplify breast cancer treatment A new method of delivering a commonly used breast cancer…
09 Aug 2012
FDA Allows WIN Consortium to Proceed with Targeted Tri-Therapy Clinical Trial in First Line Treatment of Metastatic Non Small Cell Lung Cancer
Source: WIN Consortium VILLEJUIF, France–(BUSINESS WIRE)– WIN Consortium (WIN) received the US Food and Drug Administration (FDA)’s approval to start…
09 Aug 2017
VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities to anti-HER2 treatment
• VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with…
17 Jan 2014
Announced today by GSK: VHIO joins five other international research centers of excellence as member of the Oncology Clinical and Translational Consortium (OCTC)
• GSK undertakes global consortium incorporating six prestigious cancer research centers • The Oncology Clinical and Translational Consortium (OCTC) includes…
05 Dec 2013
VHIO´s Joaquín Arribas appointed as Scientific Director of Oncology for national virtual hub of biomedical excellence
Officially announced yesterday, Joaquín Arribas, Director of Preclinical Research at VHIO, Principal Investigator of VHIO´s Growth Factors Group, and ICREA…
14 Dec 2016
Eribulin as an effective second-line therapy in patients with advanced breast cancer
The results of a clinical trial led by researchers at VHIO have established eribulin as effective therapy in patients with…
30 Jan 2015
Breast cancer diagnosed during pregnancy: safely treatable without harming foetal development
Cristina Saura, Principal Investigator of VHIO´s Breast Cancer and Melanoma Group, today reported important findings during her thesis defence directed…
21 Jul 2017
VHIO´s translational research model: an interview with Joan Seoane
Recently captured at the 2011 ASCO meeting, Joan Seoane, Director of the Vall d´Hebron Institute of Oncology´s (VHIO) Translational Research Programme talks to ecancermedicalscience
04 Jul 2011
